28 October 2026
DLA Piper advises Retension Pharmaceuticals on initial public offering
Advising firms
Deal team
12 lawyers named| Lawyer | Firm | Seniority | Practice | Office |
|---|---|---|---|---|
| Era Anagnosti Lead | DLA Piper | Partner | Not stated | Not stated |
| Mitchell Marder Lead | DLA Piper | Counsel | Not stated | Not stated |
| Andrew Gilbert Lead | DLA Piper | Partner | Not stated | Not stated |
| Gina Lee | DLA Piper | Partner | Not stated | Not stated |
| Rita Patel | DLA Piper | Partner | Not stated | Not stated |
| Christopher Mikson | DLA Piper | Partner | Not stated | Not stated |
| James McGraw | DLA Piper | Partner | Not stated | Not stated |
| Amanda Maki | DLA Piper | Of counsel | Not stated | Not stated |
| Daniel Rosenberg | DLA Piper | Associate | Not stated | Not stated |
| Drew Calamaro | DLA Piper | Associate | Not stated | Not stated |
| Tamara Lentini | DLA Piper | Associate | Not stated | Not stated |
| Atul Jain | DLA Piper | Of counsel | Not stated | Not stated |
9 more lawyers on this deal. Register free to see the full deal team, with seniority, practice and office.
REGISTER FREE SIGN INWant co-counsel patterns, repeat clients and alerts when these firms land their next deal? Get Pro.
Stated terms
- Stated value
- USD 45m (US$45 million)
- What the figure measures
- Issue size
- Client
- Retension Pharmaceuticals, Inc.Issuer
- Counterparties
- Not stated